BizCap announced it has successfully structured and secured $45 million in financing for its repeat client, Nivagen Pharmaceuticals, a specialty pharmaceuticals company engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market.

The credit facility is comprised of a $20 million revolving line of credit to facilitate working capital needs and a $25 million term loan, the proceeds of which will be used to build out a 63,500 square foot state-of-the-art sterile manufacturing R&D facility which will enable Nivagen to onshore its production capabilities. By reshoring product manufacturing, Nivagen will streamline its supply chain while significantly reducing both manufacturing costs and time to market for new product launches, ultimately providing a benefit to consumers in the form of lower costs and increased availability of certain generic products. Additionally, the new manufacturing facility will generate new revenue streams for Nivagen, including contract development and manufacturing services (CDMO) offered to third parties.
 
“BizCap exceeded our expectations a few years back when they secured important financing for us,” said Jay Shukla, founder and CEO of Nivagen. “When it came time to identify the optimal structure and cost of financing for our new manufacturing facility, ultimately requiring two different sources of capital, we didn’t hesitate – BizCap was the only call we made. BizCap is all about the relationship, not just the transaction.”

“We were pleased to once again partner with Jay and the Nivagen team to secure their financing needs,” said Chuck Doyle, president and CEO of BizCap. “This credit facility was especially critical given the recent disruptions in the pharmaceutical supply chain. It’s gratifying to play a part in Nivagen’s effort to onshore production, and we look forward to being a continued partner to them and their affiliates in the pursuit of future strategic growth initiatives.”